07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

Aggrastat tirofiban regulatory update

FDA issued a complete response letter to Medicure for an sNDA for Aggrastat tirofiban to treat patients with ST-segment elevation myocardial infarction (STEMI). Medicure said the agency asked for additional information; the company did not...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Cardiome, Mitsubishi Tanabe Pharma deal

Cardiome and Mitsubishi’s Mitsubishi Pharma Europe Ltd. subsidiary partnered to co-promote Cardiome’s Aggrastat tirofiban and Mitsubishi’s Exembol argatroban in the U.K. for a three-year term. Each company will promote the other company’s...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

Cardiome, Eddingpharm deal

Cardiome’s Correvio International S.a.r.l. subsidiary granted Eddingpharm exclusive rights to commercialize Aggrastat tirofiban in China. The non-peptide integrin alpha(2b)beta(3) ( GPIIb/IIIa; CD41/CD61) antagonist is indicated to reduce the rate of thrombotic cardiovascular...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

Aggrastat tirofiban regulatory update

Medicure submitted an sNDA to FDA for Aggrastat tirofiban to treat patients with ST segment elevation myocardial infarction (MI). The company expects a PDUFA date in July 2016. The non-peptide integrin alpha(2b)beta(3) ( GPIIb/IIIa;...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Aggrastat tirofiban regulatory update

Cardiome submitted an sNDS to Health Canada for Aggrastat tirofiban to reduce major cardiovascular events in patients with acute myocardial infarction (AMI) intended for primary percutaneous coronary intervention (PCI). The sNDS also seeks to include...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Aggrastat tirofiban regulatory update

FDA approved a label revision for cardiovascular drug Aggrastat tirofiban from Medicure to amend the dosing time for the 25 ug/kg high-dose bolus regimen to “within 5 minutes” from “over 3 minutes” in patients with...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

AOP Orphan, Cardiome deal

Cardiome granted AOP Orphan rights to market Aggrastat tirofiban in Austria, Hungary, Switzerland and other Eastern European territories. The non-peptide integrin alpha(2b)beta(3) ( GPIIb/IIIa; CD41/CD61) antagonist is approved in the U.S. and...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

Knight Therapeutics, Medicure cardiovascular news

Medicure hired Knight as an advisor to advance the company's U.S. specialty pharmaceutical business and "corporate development initiatives." Medicure has rights from Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) to Aggrastat tirofiban...
00:39 , Feb 21, 2014 |  BC Extra  |  Financial News

Cardiome raises C$15 million in follow-on

Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) raised C$15 million ($13.7 million) through the sale of 1.5 million shares at C$10 in a follow-on underwritten by Canaccord and other undisclosed banks. Shareholder CarCor Investment Holdings raised C$15...